Director at KORU Medical (KRMD) receives 3,571-share stock grant

Rhea-AI Filing Summary

CASCELLA ROBERT reported acquisition or exercise transactions in this Form 4 filing.

KORU Medical Systems director Robert Cascella received a grant of 3,571 shares of Common Stock at $4.20 per share as a compensation-related award. After this Form 4 transaction, he directly owns 98,155 shares of KORU Medical Systems common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CASCELLA ROBERT

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,571	$4.20	$15K

Holdings After Transaction: Common Stock — 98,155 shares (Direct, null)

Footnotes (1)

Key Figures

Shares granted: 3,571 shares Grant price: $4.20 per share Shares owned after grant: 98,155 shares

3 metrics

Shares granted 3,571 shares Common Stock award to director Robert Cascella

Grant price $4.20 per share Value used for the 3,571-share stock award

Shares owned after grant 98,155 shares Total direct holdings following the Form 4 transaction

Key Terms

Common Stock, grant/award acquisition, Form 4

3 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

grant/award acquisition financial

"transaction_action: "grant/award acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 05:17 PM Accepted by SEC EDGAR 07/01/2026 - 05:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASCELLA ROBERT

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		A		3,571	A	$4.2	98,155	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did KRMD director Robert Cascella report in this Form 4 filing?

Robert Cascella reported receiving a grant of 3,571 KORU Medical Systems common shares. The stock was awarded at $4.20 per share, increasing his direct holdings to 98,155 shares following the transaction, according to the Form 4 insider filing.

Was the KRMD insider transaction a purchase or a grant of shares?

The KRMD insider transaction was a grant or award of shares, not an open-market purchase. Director Robert Cascella acquired 3,571 common shares at $4.20 per share as a compensation-related stock award, as reflected by transaction code A on the Form 4.

How many KRMD shares does Robert Cascella hold after this grant?

After the reported stock grant, Robert Cascella directly owns 98,155 shares of KORU Medical Systems common stock. This total includes the newly awarded 3,571 shares at $4.20 per share that were disclosed in the Form 4 insider transaction filing.

What is the price associated with the KRMD stock award to the director?

The KRMD stock award to director Robert Cascella is recorded at $4.20 per share. This price applies to the 3,571 common shares granted to him, as disclosed in the Form 4, and is used to value the compensation-related equity award.

Does the Form 4 for KRMD indicate any stock sales by the director?

The Form 4 for KORU Medical Systems shows no stock sales by Robert Cascella. It only reports an acquisition through a grant of 3,571 common shares at $4.20 per share, bringing his direct ownership to a total of 98,155 shares.